ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Mucopolysaccharidosis Treatment Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-2U6189
Home | Market Reports | Health| Pharmacy
Global Mucopolysaccharidosis Treatment Market Size Status and Forecast 2021 2027
BUY CHAPTERS

Global Mucopolysaccharidosis Treatment Market Research Report 2025

Code: QYRE-Auto-2U6189
Report
July 2025
Pages:71
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Shire (Takeda Pharmaceutical Company Limited)
Denali Therapeutics
ArmaGen Inc.
REGENXBIO
Sangamo Therapeutics
BioMarin
Lysogene
Abeona Therapeutics, Inc.,
Ultragenyx Pharmaceutical
Genzyme Corporation

Mucopolysaccharidosis Treatment Market Size

The global market for Mucopolysaccharidosis Treatment was valued at US$ 2620 million in the year 2024 and is projected to reach a revised size of US$ 3718 million by 2031, growing at a CAGR of 5.2% during the forecast period.

Mucopolysaccharidosis Treatment Market

Mucopolysaccharidosis Treatment Market

MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Mucopolysaccharidosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mucopolysaccharidosis Treatment.
The Mucopolysaccharidosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mucopolysaccharidosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mucopolysaccharidosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Mucopolysaccharidosis Treatment Market Report

Report Metric Details
Report Name Mucopolysaccharidosis Treatment Market
Accounted market size in year US$ 2620 million
Forecasted market size in 2031 US$ 3718 million
CAGR 5.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Intravenous
  • Intracerebroventricular (ICV)
Segment by Application
  • Hospital
  • Clinic
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Shire (Takeda Pharmaceutical Company Limited), Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc., Ultragenyx Pharmaceutical, Genzyme Corporation
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Mucopolysaccharidosis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Mucopolysaccharidosis Treatment Market growing?

Ans: The Mucopolysaccharidosis Treatment Market witnessing a CAGR of 5.2% during the forecast period 2025-2031.

What is the Mucopolysaccharidosis Treatment Market size in 2031?

Ans: The Mucopolysaccharidosis Treatment Market size in 2031 will be US$ 3718 million.

Who are the main players in the Mucopolysaccharidosis Treatment Market report?

Ans: The main players in the Mucopolysaccharidosis Treatment Market are Shire (Takeda Pharmaceutical Company Limited), Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc., Ultragenyx Pharmaceutical, Genzyme Corporation

What are the Application segmentation covered in the Mucopolysaccharidosis Treatment Market report?

Ans: The Applications covered in the Mucopolysaccharidosis Treatment Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Mucopolysaccharidosis Treatment Market report?

Ans: The Types covered in the Mucopolysaccharidosis Treatment Market report are Intravenous, Intracerebroventricular (ICV)

Recommended Reports

Rare Disease Treatments

Syndrome & Ataxia Care

Disorder & Disease Therapies

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mucopolysaccharidosis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Intravenous
1.2.3 Intracerebroventricular (ICV)
1.3 Market by Application
1.3.1 Global Mucopolysaccharidosis Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mucopolysaccharidosis Treatment Market Perspective (2020-2031)
2.2 Global Mucopolysaccharidosis Treatment Growth Trends by Region
2.2.1 Global Mucopolysaccharidosis Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Mucopolysaccharidosis Treatment Historic Market Size by Region (2020-2025)
2.2.3 Mucopolysaccharidosis Treatment Forecasted Market Size by Region (2026-2031)
2.3 Mucopolysaccharidosis Treatment Market Dynamics
2.3.1 Mucopolysaccharidosis Treatment Industry Trends
2.3.2 Mucopolysaccharidosis Treatment Market Drivers
2.3.3 Mucopolysaccharidosis Treatment Market Challenges
2.3.4 Mucopolysaccharidosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mucopolysaccharidosis Treatment Players by Revenue
3.1.1 Global Top Mucopolysaccharidosis Treatment Players by Revenue (2020-2025)
3.1.2 Global Mucopolysaccharidosis Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Mucopolysaccharidosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Mucopolysaccharidosis Treatment Revenue
3.4 Global Mucopolysaccharidosis Treatment Market Concentration Ratio
3.4.1 Global Mucopolysaccharidosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mucopolysaccharidosis Treatment Revenue in 2024
3.5 Global Key Players of Mucopolysaccharidosis Treatment Head office and Area Served
3.6 Global Key Players of Mucopolysaccharidosis Treatment, Product and Application
3.7 Global Key Players of Mucopolysaccharidosis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Mucopolysaccharidosis Treatment Breakdown Data by Type
4.1 Global Mucopolysaccharidosis Treatment Historic Market Size by Type (2020-2025)
4.2 Global Mucopolysaccharidosis Treatment Forecasted Market Size by Type (2026-2031)
5 Mucopolysaccharidosis Treatment Breakdown Data by Application
5.1 Global Mucopolysaccharidosis Treatment Historic Market Size by Application (2020-2025)
5.2 Global Mucopolysaccharidosis Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Mucopolysaccharidosis Treatment Market Size (2020-2031)
6.2 North America Mucopolysaccharidosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Mucopolysaccharidosis Treatment Market Size by Country (2020-2025)
6.4 North America Mucopolysaccharidosis Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mucopolysaccharidosis Treatment Market Size (2020-2031)
7.2 Europe Mucopolysaccharidosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Mucopolysaccharidosis Treatment Market Size by Country (2020-2025)
7.4 Europe Mucopolysaccharidosis Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mucopolysaccharidosis Treatment Market Size (2020-2031)
8.2 Asia-Pacific Mucopolysaccharidosis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Mucopolysaccharidosis Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Mucopolysaccharidosis Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mucopolysaccharidosis Treatment Market Size (2020-2031)
9.2 Latin America Mucopolysaccharidosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Mucopolysaccharidosis Treatment Market Size by Country (2020-2025)
9.4 Latin America Mucopolysaccharidosis Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mucopolysaccharidosis Treatment Market Size (2020-2031)
10.2 Middle East & Africa Mucopolysaccharidosis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Mucopolysaccharidosis Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Mucopolysaccharidosis Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Shire (Takeda Pharmaceutical Company Limited)
11.1.1 Shire (Takeda Pharmaceutical Company Limited) Company Details
11.1.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
11.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Treatment Introduction
11.1.4 Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.1.5 Shire (Takeda Pharmaceutical Company Limited) Recent Development
11.2 Denali Therapeutics
11.2.1 Denali Therapeutics Company Details
11.2.2 Denali Therapeutics Business Overview
11.2.3 Denali Therapeutics Mucopolysaccharidosis Treatment Introduction
11.2.4 Denali Therapeutics Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.2.5 Denali Therapeutics Recent Development
11.3 ArmaGen
11.3.1 ArmaGen Company Details
11.3.2 ArmaGen Business Overview
11.3.3 ArmaGen Mucopolysaccharidosis Treatment Introduction
11.3.4 ArmaGen Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.3.5 ArmaGen Recent Development
11.4 REGENXBIO Inc.
11.4.1 REGENXBIO Inc. Company Details
11.4.2 REGENXBIO Inc. Business Overview
11.4.3 REGENXBIO Inc. Mucopolysaccharidosis Treatment Introduction
11.4.4 REGENXBIO Inc. Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.4.5 REGENXBIO Inc. Recent Development
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Details
11.5.2 Sangamo Therapeutics Business Overview
11.5.3 Sangamo Therapeutics Mucopolysaccharidosis Treatment Introduction
11.5.4 Sangamo Therapeutics Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.5.5 Sangamo Therapeutics Recent Development
11.6 BioMarin
11.6.1 BioMarin Company Details
11.6.2 BioMarin Business Overview
11.6.3 BioMarin Mucopolysaccharidosis Treatment Introduction
11.6.4 BioMarin Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.6.5 BioMarin Recent Development
11.7 Lysogene
11.7.1 Lysogene Company Details
11.7.2 Lysogene Business Overview
11.7.3 Lysogene Mucopolysaccharidosis Treatment Introduction
11.7.4 Lysogene Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.7.5 Lysogene Recent Development
11.8 Abeona Therapeutics Inc.
11.8.1 Abeona Therapeutics Inc. Company Details
11.8.2 Abeona Therapeutics Inc. Business Overview
11.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Treatment Introduction
11.8.4 Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.8.5 Abeona Therapeutics Inc. Recent Development
11.9 Ultragenyx Pharmaceutical
11.9.1 Ultragenyx Pharmaceutical Company Details
11.9.2 Ultragenyx Pharmaceutical Business Overview
11.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Treatment Introduction
11.9.4 Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.9.5 Ultragenyx Pharmaceutical Recent Development
11.10 Genzyme Corporation
11.10.1 Genzyme Corporation Company Details
11.10.2 Genzyme Corporation Business Overview
11.10.3 Genzyme Corporation Mucopolysaccharidosis Treatment Introduction
11.10.4 Genzyme Corporation Revenue in Mucopolysaccharidosis Treatment Business (2020-2025)
11.10.5 Genzyme Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Shire (Takeda Pharmaceutical Company Limited)
Denali Therapeutics
ArmaGen Inc.
REGENXBIO
Sangamo Therapeutics
BioMarin
Lysogene
Abeona Therapeutics, Inc.,
Ultragenyx Pharmaceutical
Genzyme Corporation
List of Tables
 Table 1. Global Mucopolysaccharidosis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Intravenous
 Table 3. Key Players of Intracerebroventricular (ICV)
 Table 4. Global Mucopolysaccharidosis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Mucopolysaccharidosis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Mucopolysaccharidosis Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Mucopolysaccharidosis Treatment Market Share by Region (2020-2025)
 Table 8. Global Mucopolysaccharidosis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Mucopolysaccharidosis Treatment Market Share by Region (2026-2031)
 Table 10. Mucopolysaccharidosis Treatment Market Trends
 Table 11. Mucopolysaccharidosis Treatment Market Drivers
 Table 12. Mucopolysaccharidosis Treatment Market Challenges
 Table 13. Mucopolysaccharidosis Treatment Market Restraints
 Table 14. Global Mucopolysaccharidosis Treatment Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Mucopolysaccharidosis Treatment Market Share by Players (2020-2025)
 Table 16. Global Top Mucopolysaccharidosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Treatment as of 2024)
 Table 17. Ranking of Global Top Mucopolysaccharidosis Treatment Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Mucopolysaccharidosis Treatment Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Mucopolysaccharidosis Treatment, Headquarters and Area Served
 Table 20. Global Key Players of Mucopolysaccharidosis Treatment, Product and Application
 Table 21. Global Key Players of Mucopolysaccharidosis Treatment, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Mucopolysaccharidosis Treatment Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Mucopolysaccharidosis Treatment Revenue Market Share by Type (2020-2025)
 Table 25. Global Mucopolysaccharidosis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Mucopolysaccharidosis Treatment Revenue Market Share by Type (2026-2031)
 Table 27. Global Mucopolysaccharidosis Treatment Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Mucopolysaccharidosis Treatment Revenue Market Share by Application (2020-2025)
 Table 29. Global Mucopolysaccharidosis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Mucopolysaccharidosis Treatment Revenue Market Share by Application (2026-2031)
 Table 31. North America Mucopolysaccharidosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Mucopolysaccharidosis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Mucopolysaccharidosis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Mucopolysaccharidosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Mucopolysaccharidosis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Mucopolysaccharidosis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Mucopolysaccharidosis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Mucopolysaccharidosis Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Mucopolysaccharidosis Treatment Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Mucopolysaccharidosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Mucopolysaccharidosis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Mucopolysaccharidosis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Mucopolysaccharidosis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Mucopolysaccharidosis Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Mucopolysaccharidosis Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Shire (Takeda Pharmaceutical Company Limited) Company Details
 Table 47. Shire (Takeda Pharmaceutical Company Limited) Business Overview
 Table 48. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Treatment Product
 Table 49. Shire (Takeda Pharmaceutical Company Limited) Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 50. Shire (Takeda Pharmaceutical Company Limited) Recent Development
 Table 51. Denali Therapeutics Company Details
 Table 52. Denali Therapeutics Business Overview
 Table 53. Denali Therapeutics Mucopolysaccharidosis Treatment Product
 Table 54. Denali Therapeutics Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 55. Denali Therapeutics Recent Development
 Table 56. ArmaGen Company Details
 Table 57. ArmaGen Business Overview
 Table 58. ArmaGen Mucopolysaccharidosis Treatment Product
 Table 59. ArmaGen Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 60. ArmaGen Recent Development
 Table 61. REGENXBIO Inc. Company Details
 Table 62. REGENXBIO Inc. Business Overview
 Table 63. REGENXBIO Inc. Mucopolysaccharidosis Treatment Product
 Table 64. REGENXBIO Inc. Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 65. REGENXBIO Inc. Recent Development
 Table 66. Sangamo Therapeutics Company Details
 Table 67. Sangamo Therapeutics Business Overview
 Table 68. Sangamo Therapeutics Mucopolysaccharidosis Treatment Product
 Table 69. Sangamo Therapeutics Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 70. Sangamo Therapeutics Recent Development
 Table 71. BioMarin Company Details
 Table 72. BioMarin Business Overview
 Table 73. BioMarin Mucopolysaccharidosis Treatment Product
 Table 74. BioMarin Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 75. BioMarin Recent Development
 Table 76. Lysogene Company Details
 Table 77. Lysogene Business Overview
 Table 78. Lysogene Mucopolysaccharidosis Treatment Product
 Table 79. Lysogene Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 80. Lysogene Recent Development
 Table 81. Abeona Therapeutics Inc. Company Details
 Table 82. Abeona Therapeutics Inc. Business Overview
 Table 83. Abeona Therapeutics Inc. Mucopolysaccharidosis Treatment Product
 Table 84. Abeona Therapeutics Inc. Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 85. Abeona Therapeutics Inc. Recent Development
 Table 86. Ultragenyx Pharmaceutical Company Details
 Table 87. Ultragenyx Pharmaceutical Business Overview
 Table 88. Ultragenyx Pharmaceutical Mucopolysaccharidosis Treatment Product
 Table 89. Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 90. Ultragenyx Pharmaceutical Recent Development
 Table 91. Genzyme Corporation Company Details
 Table 92. Genzyme Corporation Business Overview
 Table 93. Genzyme Corporation Mucopolysaccharidosis Treatment Product
 Table 94. Genzyme Corporation Revenue in Mucopolysaccharidosis Treatment Business (2020-2025) & (US$ Million)
 Table 95. Genzyme Corporation Recent Development
 Table 96. Research Programs/Design for This Report
 Table 97. Key Data Information from Secondary Sources
 Table 98. Key Data Information from Primary Sources
 Table 99. Authors List of This Report


List of Figures
 Figure 1. Mucopolysaccharidosis Treatment Picture
 Figure 2. Global Mucopolysaccharidosis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Mucopolysaccharidosis Treatment Market Share by Type: 2024 VS 2031
 Figure 4. Intravenous Features
 Figure 5. Intracerebroventricular (ICV) Features
 Figure 6. Global Mucopolysaccharidosis Treatment Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Mucopolysaccharidosis Treatment Market Share by Application: 2024 VS 2031
 Figure 8. Hospital Case Studies
 Figure 9. Clinic Case Studies
 Figure 10. Other Case Studies
 Figure 11. Mucopolysaccharidosis Treatment Report Years Considered
 Figure 12. Global Mucopolysaccharidosis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Mucopolysaccharidosis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Mucopolysaccharidosis Treatment Market Share by Region: 2024 VS 2031
 Figure 15. Global Mucopolysaccharidosis Treatment Market Share by Players in 2024
 Figure 16. Global Top Mucopolysaccharidosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mucopolysaccharidosis Treatment as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Mucopolysaccharidosis Treatment Revenue in 2024
 Figure 18. North America Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Mucopolysaccharidosis Treatment Market Share by Country (2020-2031)
 Figure 20. United States Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Mucopolysaccharidosis Treatment Market Share by Country (2020-2031)
 Figure 24. Germany Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Mucopolysaccharidosis Treatment Market Share by Region (2020-2031)
 Figure 32. China Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Mucopolysaccharidosis Treatment Market Share by Country (2020-2031)
 Figure 40. Mexico Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Mucopolysaccharidosis Treatment Market Share by Country (2020-2031)
 Figure 44. Turkey Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Mucopolysaccharidosis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Shire (Takeda Pharmaceutical Company Limited) Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 48. Denali Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 49. ArmaGen Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 50. REGENXBIO Inc. Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 51. Sangamo Therapeutics Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 52. BioMarin Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 53. Lysogene Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 54. Abeona Therapeutics Inc. Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 55. Ultragenyx Pharmaceutical Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 56. Genzyme Corporation Revenue Growth Rate in Mucopolysaccharidosis Treatment Business (2020-2025)
 Figure 57. Bottom-up and Top-down Approaches for This Report
 Figure 58. Data Triangulation
 Figure 59. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Mucopolysaccharidosis Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Mucopolysaccharidosis MPS Treatment Market Research Report 2024
Global Sphingolipidoses Treatment Market Research Report 2025
Global Hunter Syndrome Treatment Market Insights Forecast to 2030
Alpha Mannosidosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Lysosomal Storage Diseases Market Research Report 2024
Morquio Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Lysosomal Storage Disease Treatment Market Research Report 2024
Global Mucopolysaccharidosis II Market Research Report 2025
Lysosomal Storage Disorders Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Lysosomal Storage Disease Treatment Drugs Market Research Report 2024
Global Pompe Disease Treatment Market Research Report 2024
Global Fabry Disease Treatment Market Insights Forecast to 2030
GM1 Gangliosidosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Gaucher Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Mucopolysaccharidosis Type IVA Drug Market Research Report 2024
Global Lysosomal Storage Disorder Drugs Market Research Report 2024
Gaucher Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Polymyositis Treatment Market Insights Forecast to 2030
Global Musculoskeletal System Disorder Therapeutics Market Research Report 2024

RELATED REPORTS

Global Multi-use Capsule-based Dry Powder Inhaler Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10O16568
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Jet Lag Medicine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0R20253
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Ruxolitinib Phosphate Tablets Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3G16891
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global NaSSAs Antidepressants Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4B16895
Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions